A method for extracting flavone aglycones in Chrysanthemum morifolium is provided. The method includes: (a) immersing a Chrysanthemum morifolium raw material in water or an aqueous solution to perform an immersion procedure for 3.5 hours or more to obtain an immersion sample; and (b) adding an extraction solvent to the immersion sample to perform an extraction procedure 5-60 minutes to obtain an extract. The Chrysanthemum morifolium raw material includes at least one of the following parts of Chrysanthemum morifolium: whole plant, roots, stems, leaves and flowers.

A method for extracting flavone aglycones in Chrysanthemum morifolium is provided. The method includes: (a) immersing a Chrysanthemum morifolium raw material in water or an aqueous solution to perform an immersion procedure for 3.5 hours or more to obtain an immersion sample; and (b) adding an extraction solvent to the immersion sample to perform an extraction procedure 5-60 minutes to obtain an extract. The Chrysanthemum morifolium raw material includes at least one of the following parts of Chrysanthemum morifolium: whole plant, roots, stems, leaves and flowers.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

The present invention provides a pharmaceutical composition comprising a mushroom, a rhizome, a fruit, a leaf, a flower, an alga, an energy-rich liquid, a salt-rich liquid, an assist agent and an anti-oxide agent. Said pharmaceutical composition has ability to protect liver, improve autoimmunity, reduce pain caused by cancer, protect an organ from the side-effects caused by chemical cancer drugs and increase the functions of chemical cancer drugs.

An anti-gout composition including the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient shows substantially greater inhibitory effects on xanthine oxidase than when Chrysanthemum indicum or Cinnamomum cassia is used separately. An animal model treated with the mixed extract of Chrysanthemum indicum and Cinnamomum cassia experienced a decrease in uric acid in serum and in urine. The mixed extract of Chrysanthemum indicum and Cinnamomum cassia is an active ingredient induced from a natural material, and, accordingly, the mixed extract is safe and a source material therefor is easily provided. Accordingly, the mixed extract can be widely used in gout-related industries.

An anti-gout composition including the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient shows substantially greater inhibitory effects on xanthine oxidase than when Chrysanthemum indicum or Cinnamomum cassia is used separately. An animal model treated with the mixed extract of Chrysanthemum indicum and Cinnamomum cassia experienced a decrease in uric acid in serum and in urine. The mixed extract of Chrysanthemum indicum and Cinnamomum cassia is an active ingredient induced from a natural material, and, accordingly, the mixed extract is safe and a source material therefor is easily provided. Accordingly, the mixed extract can be widely used in gout-related industries.

Compositions for topical use and having a melanin synthesis-inhibiting activity that include an amount of a botanical extract of at least one of Aspalathus Linearis, Matricaria, Saxifraga, Astragalus, Taraxacum officinale/mongolicum, Ferula varia/foetida, Carthamus tinctorius, Sophora flavescentis, or Chrysanthemum morifolium effective to reduce melanin synthesis are described. Methods for inhibiting melanin synthesis and for skin whitening are also described.

Compositions for topical use and having a melanin synthesis-inhibiting activity that include an amount of a botanical extract of at least one of Aspalathus Linearis, Matricaria, Saxifraga, Astragalus, Taraxacum officinale/mongolicum, Ferula varia/foetida, Carthamus tinctorius, Sophora flavescentis, or Chrysanthemum morifolium effective to reduce melanin synthesis are described. Methods for inhibiting melanin synthesis and for skin whitening are also described.

Compositions for topical use and having a melanin synthesis-inhibiting activity that include an amount of a botanical extract of at least one of Aspalathus Linearis, Matricaria, Saxifraga, Astragalus, Taraxacum officinale/mongolicum, Ferula varia/foetida, Carthamus tinctorius, Sophora flavescentis, or Chrysanthemum morifolium effective to reduce melanin synthesis are described. Methods for inhibiting melanin synthesis and for skin whitening are also described.